Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
18.20
-0.30 (-1.62%)
At close: Nov 20, 2024, 4:00 PM
18.19
-0.01 (-0.05%)
After-hours: Nov 20, 2024, 7:27 PM EST
Aligos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 6 | 15.53 | 13.91 | 4.36 | - | - | |
| Revenue Growth (YoY) | -63.40% | 11.66% | 219.04% | - | - | - | |
| Cost of Revenue | 76.5 | 73.04 | 85.08 | 104.15 | 79.89 | - | |
| Gross Profit | -70.5 | -57.51 | -71.17 | -99.79 | -79.89 | - | |
| Selling, General & Admin | 23.37 | 29.89 | 26.41 | 28.53 | 17.94 | 10.1 | |
| Research & Development | - | - | - | - | - | 44.04 | |
| Operating Expenses | 23.37 | 29.89 | 26.41 | 28.53 | 17.94 | 54.13 | |
| Operating Income | -93.86 | -87.4 | -97.58 | -128.32 | -97.83 | -54.13 | |
| Interest Expense | - | - | - | - | -0.24 | -0.04 | |
| Interest & Investment Income | 2.95 | 4.3 | 1.52 | 0.24 | 1.26 | 1.6 | |
| Currency Exchange Gain (Loss) | -0.05 | -0.05 | -0.04 | -0.01 | 0.12 | -0.05 | |
| Other Non Operating Income (Expenses) | 15.01 | -3.01 | 0.16 | -0.1 | -11.68 | 0.44 | |
| EBT Excluding Unusual Items | -75.96 | -86.16 | -95.94 | -128.19 | -108.38 | -52.18 | |
| Asset Writedown | -0.72 | -0.72 | - | - | - | - | |
| Pretax Income | -76.68 | -86.88 | -95.94 | -128.19 | -108.38 | -52.18 | |
| Income Tax Expense | 0.27 | 0.8 | 0.11 | 0.14 | 0.16 | 0.09 | |
| Net Income | -76.95 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | |
| Net Income to Common | -76.95 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | |
| Shares Outstanding (Basic) | 6 | 3 | 2 | 2 | 0 | 0 | |
| Shares Outstanding (Diluted) | 6 | 3 | 2 | 2 | 0 | 0 | |
| Shares Change (YoY) | 246.07% | 50.51% | 7.13% | 299.02% | 397.62% | 68.42% | |
| EPS (Basic) | -12.89 | -34.11 | -56.24 | -80.50 | -271.68 | -650.96 | |
| EPS (Diluted) | -12.89 | -34.11 | -56.25 | -80.50 | -271.68 | -650.96 | |
| Free Cash Flow | -85.11 | -79.02 | -80.33 | -116.55 | -76.33 | -49.55 | |
| Free Cash Flow Per Share | -14.26 | -30.74 | -47.04 | -73.11 | -191.04 | -617.20 | |
| Operating Margin | -1565.18% | -562.84% | -701.66% | -2943.82% | - | - | |
| Profit Margin | -1283.19% | -564.61% | -690.63% | -2944.07% | - | - | |
| Free Cash Flow Margin | -1419.16% | -508.83% | -577.64% | -2673.87% | - | - | |
| EBITDA | -92.68 | -85.84 | -95.27 | -125.3 | -95.1 | -52.74 | |
| D&A For EBITDA | 1.18 | 1.56 | 2.31 | 3.02 | 2.74 | 1.4 | |
| EBIT | -93.86 | -87.4 | -97.58 | -128.32 | -97.83 | -54.13 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.